Skip to main content
. Author manuscript; available in PMC: 2011 Oct 24.
Published in final edited form as: J Mol Cell Cardiol. 2004 Dec 8;38(1):127–134. doi: 10.1016/j.yjmcc.2004.10.006

Fig. 1.

Fig. 1

Experimental protocol. Nine groups of mice were used. On day 1, mice in group I (n = 6, sham PC) received sham PC, while mice in group II (n = 10, late PC 24 h) and group III (n = 10, late PC 72 h) underwent six cycles of 4-min coronary occlusion (O)/4-min reperfusion (R). Mice in groups IV (n = 9),VI (n = 9), and VIII (n = 7) received 3.54 mg/kg of inactive CORM-3 (iCORM-3) as an i.v. infusion for 60 min. Mice in groups V (n = 10), VII (n = 10), and IX (n = 11) received 3.54 mg/kg of CORM-3 as an i.v. infusion for 60 min. In groups I, II, IV, and V, mice underwent a 30-min coronary occlusion followed by 24 h of reperfusion on day 2 (24 h after sham PC, ischemic PC, inactive CORM-3, or CORM-3). In groups III, VI, and VII, mice underwent a 30-min coronary occlusion followed by 24 h of reperfusion on day 4 (72 h after ischemic PC, inactive CORM-3 or CORM-3). In groups VIII and IX, mice underwent a 30-min coronary occlusion followed by 24 h of reperfusion on day 6 (120 h after inactive CORM-3 or CORM-3).